- Home
- MNPR vs ANVS Comparison
MNPR vs ANVS Comparison
Compare MNPR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ANVS
- Stock Information
- Founded
- MNPR 2014
- ANVS 2008
- Country
- MNPR United States
- ANVS United States
- Employees
- MNPR N/A
- ANVS N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- ANVS Health Care
- Exchange
- MNPR Nasdaq
- ANVS Nasdaq
- Market Cap
- MNPR 113.5M
- ANVS 92.6M
- IPO Year
- MNPR 2019
- ANVS 2020
- Fundamental
- Price
- MNPR $28.54
- ANVS $5.01
- Analyst Decision
- MNPR Strong Buy
- ANVS Strong Buy
- Analyst Count
- MNPR 4
- ANVS 6
- Target Price
- MNPR $38.50
- ANVS $29.67
- AVG Volume (30 Days)
- MNPR 59.4K
- ANVS 488.6K
- Earning Date
- MNPR 11-08-2024
- ANVS 11-08-2024
- Dividend Yield
- MNPR N/A
- ANVS N/A
- EPS Growth
- MNPR N/A
- ANVS N/A
- EPS
- MNPR N/A
- ANVS N/A
- Revenue
- MNPR N/A
- ANVS N/A
- Revenue This Year
- MNPR N/A
- ANVS N/A
- Revenue Next Year
- MNPR N/A
- ANVS N/A
- P/E Ratio
- MNPR N/A
- ANVS N/A
- Revenue Growth
- MNPR N/A
- ANVS N/A
- 52 Week Low
- MNPR $1.55
- ANVS $4.21
- 52 Week High
- MNPR $38.50
- ANVS $20.00
- Technical
- Relative Strength Index (RSI)
- MNPR 60.16
- ANVS 44.02
- Support Level
- MNPR $24.00
- ANVS $4.61
- Resistance Level
- MNPR $26.52
- ANVS $4.95
- Average True Range (ATR)
- MNPR 2.42
- ANVS 0.38
- MACD
- MNPR 0.32
- ANVS 0.07
- Stochastic Oscillator
- MNPR 68.85
- ANVS 40.40
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.